The relationship between ApoA5 and plasma TG metabolism has been well established; however, the influence of ApoA5 on NAFLD and atherosclerotic cardiovascular disease (ASCVD) has remained largely elusive. Here, APOA5 is linked to metabolic dysfunction-associated steatotic liver disease.